KalVista Pharmaceuticals, Inc. (KALV)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$27.000.00%
Close 2026-06-12 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
Warn: Primary pillar under pressure — KalVista addresses regulatory challenges related to listing standards: Delisting notice filed vs target of no delisting.
KalVista aims for $35 million revenue in 2025. It is working to fix regulatory problems. The company recently completed a merger. These steps could lead to future profits.
KalVista is still losing money and faces listing rule problems. Many directors resigned. Revenue and earnings estimates show losses continuing next year.
The market has no clear consensus on growth or earnings. Our fair value is about $7 per share, reflecting uncertainty. We see risk from regulatory and financial challenges.
Breaks if: Default on debt or liquidity crisis occurs
Breaks if: EPS remains negative or below 0 in FY27
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a speculative growth opportunity in the healthcare sector. KALV is currently navigating through a volatile management phase while focusing on revenue growth from its EKTERLY product.
The market currently reflects a premium valuation compared to peers, indicating that some fragility is priced in. This suggests that investors may expect significant improvements or changes in the company's performance.
KALV's fundamentals may show gradual improvement as management focuses on reducing operating losses and increasing EKTERLY revenue. However, the company remains loss-making, which adds uncertainty to its financial trajectory.
The future performance of KALV hinges on management's ability to sustain EKTERLY's revenue growth and navigate regulatory challenges. Additionally, broader sector momentum and economic conditions will play a crucial role in shaping its prospects.
The most important moves since the prior daily snapshot.
Our read on the company is unchanged since the prior snapshot.
as of 2026-09-04
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Breaks if: regulatory problems cause delisting or trading halt
Management is addressing regulatory challenges related to listing standards.
Breaks if: revenue falls below $30 million in FY25
Over the next 1 to 3 years, KALV's performance will depend on effective management execution and external market factors. Not investment advice.